Patients at age ≥ 18 years

Diagnosed with melanoma stage (independent of stage)

Assigned to receive an immunotherapeutic regimen (PD-1 antibody +/- Ipilimumab)

Sufficient German language skills

Willing to train at the exercise facilities twice per week and to take part in the scheduled testing at the National Center for Tumor Diseases

Signed informed consent

Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment